The relationships among cortical volumetric bone mineral density (CortBMD) and comprehensive measures of mineral metabolism have not been addressed in chronic kidney disease (CKD).
C
hronic kidney disease (CKD) poses multiple threats to bone accrual during growth. We reported that secondary hyperparathyroidism was associated with declines in peripheral quantitative computed tomography (pQCT) measures of cortical volumetric bone mineral density (CortBMD) in childhood CKD (1) . Although the fracture implications of these findings are not known, a study in adult hemodialysis patients demonstrated that a low pQCT CortBMD was strongly associated with prevalent fractures (2) .
Recent cross-sectional bone histomorphometry studies in children demonstrated that defective mineralization was present as early as stage 2 CKD, and the prevalence increased with progressive CKD severity, exceeding 90% in CKD 5D (dialysis) (3) . In contrast, a mineralization defect was observed in only 3% of adults on dialysis (4) . Therefore, the growing skeleton may be uniquely vulnerable to impaired mineralization in CKD.
In children with predialysis CKD, lower serum calcium and higher PTH concentrations were associated with defective mineralization (3), whereas higher fibroblast growth factor 23 (FGF-23) was associated with better mineralization in children on dialysis. The development of treatments for CKD mineral and bone disorder requires a better understanding of the impact of mineral metabolism on CortBMD as well as interactions with growth.
Recent studies highlight the need to consider vitamin D-binding protein (DBP) and vitamin D catabolism in CKD. Bhan et al (5) demonstrated that bioavailable 25-hydroxyvitamin D [25(OH)D], ie, the fraction not bound to DBP, was better correlated with measures of mineral metabolism than total 25(OH)D in adults on hemodialysis. In addition, reduced vitamin D catabolism, as reflected by lower serum concentrations of 24,25-dihydroxyvitamin D [24, 25(OH) 2 D], has also been identified in CKD (6) .
This prospective cohort study is the first to examine associations between CortBMD and serum calcium, phosphorus, PTH, FGF-23, and vitamin D concentrations [including 24,25(OH) 2 D, free and bioavailable 25(OH)D] in a large cohort of children, adolescents, and young adults with CKD. CortBMD reference data were generated in 675 concurrent healthy participants. The primary objectives were to identify determinants of baseline CortBMD Z-scores and changes in CortBMD Z-scores in childhood CKD. Secondary objectives were to compare the associations of total, free, and bioavailable 25(OH)D concentrations with CortBMD and to assess whether baseline CortBMD Z-score was associated with subsequent fracture.
Materials and Methods

Study participants
This study was part of a larger study of bone health in 205 participants with CKD, ages 5-21 years, conducted at the Children's Hospital of Philadelphia (CHOP) and Cincinnati Children's Hospital Medical Center (CCHMC) (1, (7) (8) (9) (10) (8) . Of these, 171 had a pQCT scan performed within 1 month of their blood sample and are included in this cross-sectional analysis. Longitudinal analyses were performed in the subset of 89 with both CortBMD and vitamin D measured 12 Ϯ 4 months later. Of the 82 participants excluded from the longitudinal analyses, 25 had no further follow-up, 33 underwent renal transplantation during the follow-up interval, and 24 did not have a usable pQCT scan or vitamin D in this time frame. The 170 participants with a baseline CortBMD measure and 1 or more follow-up visits were included in the fracture analysis.
The reference population of 675 healthy participants was recruited from practices in the Philadelphia area (1, 8 -11) . The Institutional Review Boards at CHOP and CCHMC approved the study protocol. Informed consent was obtained from participants 18 years of age or older and assent with parental consent from subjects younger than 18 years.
Anthropometry
Height was measured with a stadiometer and weight with a digital scale. Height and body mass index (BMI; kilograms per square meter) Z-scores were calculated using national reference data (12) .
Laboratory measurements
Serum 25(OH)D and 1,25(OH) 2 D concentrations were measured by I 125 RIA (DiaSorin Inc, Stillwater, Minnesota) (13). Intraassay coefficients of variation (CVs) were 2.2% and 7%-11%, respectively (14) . Serum 24,25(OH) 2 D was measured by combined tandem mass spectrometry (6) with an interassay CV of 8.6%.
Serum DBP was measured in duplicate (CV Ͻ 10%) using an ELISA (R&D Systems, Minneapolis, MN). The interassay CV was 1.6%-3.6%, and recovery was 98%-103%. Intact (iPTH) and bioactive PTH (1-84PTH) concentrations were measured by RIA with CVs of 3%-10% (Scantibodies Laboratory, Santee, California) (15) . Intact FGF-23 was measured via an ELISA (Kainos Laboratories Inc, Tokyo, Japan; CV 6.7%-12.4%). Serum albumin and creatinine were measured by spectrophotometric enzymatic assay (Vitros; Johnson & Johnson Co, Rochester, New York) with CVs of 1%-2% and 1%-5%, respectively. Serum calcium and phosphorus were measured using standard clinical methods with CVs of 1.3% and 2.1% or less, respectively; calcium was corrected for albumin (16) . Estimated glomerular filtration rate (eGFR) was calculated based on height and serum creatinine using the Chronic Kidney Disease in Children Study equation (17 (19, 20) .
Peripheral quantitative computed tomography
This study was limited to measures of CortBMD to examine associations with measures of mineral metabolism. Kovanlikaya et al (21) demonstrated that rickets resulted in marked decreases in quantitative computed tomography measures of femur CortBMD. In contrast, pQCT measures of trabecular BMD include the marrow space and cannot distinguish between disease effects on trabecular structure vs mineralization. Bone measures were obtained in the midshaft of the tibia, 38% proximal to the distal growth plate, using a Stratec XCT2000 device (Orthometrix, White Plains, New York) as described (9, 10) . The 38% site was used to minimize partial-volume effects, which may result in an underestimation of CortBMD in disorders characterized by cortical thinning. Analyses demonstrating absence of partial-volume effects were provided previously (10) . The radiation effective dose equivalent was less than 0.01 Sv. The manufacturer's hydroxyapatite phantom was scanned daily. A test-retest precision study in 60 children and adolescents yielded an in vivo CV for CortBMD of 0.5%.
We reported that CortBMD in healthy children increased with age and was greater in females and blacks, and the sex and race effects varied with age (11) . Therefore, CortBMD results were converted to sex-and race (black vs other)-specific Z-scores relative to age using the LMS method (1, 9, 10) . This method accounts for the nonlinearity, heteroscedasticity, and skew of bone data in growing children (22) .
Disease characteristics and medications
Medical charts were reviewed for disease and treatment characteristics. Information on current medications and sources of vitamin D supplementation were obtained by questionnaire and confirmed in the medical record. Participants/guardians were interviewed at all study visits regarding details of new fractures, and all fractures that occurred after the baseline visit were confirmed by review of radiology reports.
Statistical analyses
All analyses were performed using STATA 11.0 (Stata Corp, College Station, Texas). A 2-sided P Ͻ .05 was considered statistically significant. Continuous variables were reported as mean Ϯ SD values or as median and interquartile range (IQR) if skewed. Group differences were assessed using the Student's t test , ANOVA, Wilcoxon rank sum, Kruskal-Wallis, or 2 tests as appropriate, and the nptrend command in STATA as the nonparametric test for trend across ordered groups. Correlations were assessed by Pearson product moment or Spearman's rank correlations. The corcor program was used to test the equality of 2 dependent correlations. Skewed variables were natural log transformed (23) .
Multivariable linear regression analysis was used to evaluate correlates of the CortBMD Z-score at enrollment, testing age, sex, race (black vs other), Tanner stage, BMI Z-score, study location (CHOP vs CCHMC), underlying diagnosis, CKD stage, acidosis (serum bicarbonate Ͻ 19 mmol/L), glucocorticoid and vitamin D sterol therapy at the time of the visit, and serum concentrations of PTH (iPTH and 1-84PTH), FGF-23, 25(OH)D (total, free, and bioavailable), 1,25(OH) 2 D, 24,25(OH) 2 D, phosphorus, and calcium. Model assumptions were assessed via graphical checks, eg, to assess linearity of relationships and normality of residuals.
Multivariable linear regression was used to evaluate the correlates of change in the CortBMD Z-score. In our recent study in this cohort (1), we demonstrated that the baseline CortBMD Z-score, baseline age, change in tibia length, and study location (CHOP) were inversely related to the change in the CortBMD Z-score. Therefore, a base model with these covariates was used to test the associations between change in the CortBMD Z-score and the following: sex, race, baseline and change in the BMI Z-score, the underlying diagnosis, CKD severity at baseline and change in renal function (decline in eGFR Ͼ 10 mL/min per 1.73 m 2 or starting dialysis vs all others), acidosis, baseline glucocorticoid and vitamin D sterol therapy, initiating sterol therapy, and the baseline value of and change in all measures of mineral metabolism. Cox regression analysis, adjusted for sex and age, was used to determine whether the baseline CortBMD Z-score was associated with fracture [hazard ratio (HR) for time to first fracture].
Results
Participant characteristics (Table 1)
The baseline characteristics in Table 1 were comparable in participants with vs without a follow-up visit, with the exception of sex (66% vs 51% male) and CKD severity (CKD stages 2-3: 53% vs 26%; CKD stages 4 -5: 26% vs 34%; and CKD stage 5D: 21% vs 40%), which can be explained by the 33 participants excluded for intervening transplantation. Vitamin D sterol use was more common than nutritional vitamin D supplementation, because participants were enrolled before the study sites measured 25(OH)D as part of clinical care. The vitamin D assays were performed in batches often well after sample collection, and neither participants nor their providers were given the results. Only 11 of 28 participants on supplemental vitamin D had 25(OH)D concentrations less than 20 ng/mL.
Measures of mineral metabolism by CKD stage (Table 2)
Calcium did not differ by CKD stage. Greater CKD severity was associated with greater concentrations of serum phosphorus, iPTH, 1-84PTH, and FGF-23, and with lower total, free, and bioavailable 25(OH)D, 1,25(OH) 2 D, and 24,25(OH) 2 D (all P Ͻ .001).
Association between total vs free and bioavailable 25(OH)D and CortBMD Z-score
CortBMD Z-score was associated with total, free and bioavailable 25(OH)D (Table 3 ). There were no significant differences among the correlation coefficients for total, free, and bioavailable 25(OH)D with CortBMD Zscore (all P Ն .3).
CortBMD Z-score
The mean CortBMD Z-score was Ϫ0.06 Ϯ 1.31. Table  2 summarizes CortBMD Z-score according to CKD stage. Table 3 shows the bivariate correlation matrix for Cort-BMD Z-score and measures of mineral metabolism. Greater concentrations of calcium, 25(OH)D, and 24,25(OH) 2 D were associated with greater CortBMD Zscore, and higher concentrations of phosphorus and iPTH with lower CortBMD Z-score. In bivariate analysis, older age (Ϫ0.08 SD per year, P ϭ .002), black race (Ϫ0.46 SD, P Ͻ .05), study site of CHOP (Ϫ0.64 SD, P ϭ .002), acidosis (Ϫ0.71 SD, P ϭ .04), focal segmental glomerulosclerosis (vs other diagnoses, Ϫ0.56 SD, P ϭ .03), CKD stages 4 -5 (vs stages 2-3, Ϫ0.84 SD, P ϭ .001), and vitamin D sterol therapy (Ϫ0.55 SD, P ϭ .007) were associated with lower CortBMD Z-score; glucocorticoid exposure (0.65 SD, P ϭ .03) was associated with greater CortBMD Z-score. There was no difference in mean CortBMD Z-score by dialysis modality (hemodialysis Ϫ0.01 vs peritoneal dialysis 0.01, P ϭ .97).
In multivariable analyses, calcium, 25(OH)D, and glucocorticoid exposure were positively associated, and iPTH and 1,25(OH) 2 D concentrations were negatively associated with CortBMD Z-score. The sequential models in Table 4 . Being on vitamin D sterol therapy was associated with lower CortBMD Z-score, but this was explained by higher iPTH concentrations in those on sterols (model 6 vs 7). The variance inflation factor for these models was Յ 1.35 indicating that there was no problematic collinearity. 24,25(OH) 2 D, phosphorus, race, Tanner stage, acidosis, and underlying disease were not associated with Cort-BMD Z-score in multivariable analysis. Sex, BMI Z-score, and FGF-23 were not associated with CortBMD Z-score in bivariate or multivariable analyses. Table 5 shows the final model with the difference in CortBMD Z-score associated with each independent determinant displayed in clinically interpretable measures. Substituting 1-84PTH for iPTH had no effect on the model findings. Adjustment for CKD stage did not impact model findings except for modestly attenuating the ␤-coefficient for 25(OH)D (0.18 to 0.16 per 10 ng/mL difference, P ϭ .06). The ␤-coefficients and P values for 1,25(OH) 2 D and calcium did not change significantly. In multivariate analyses, CKD stages 4 -5 were associated with lower CortBMD Z-score (vs CKD stages 2-3, Ϫ0.51 SD, P ϭ .03).
Changes in CortBMD Z
The median time between visits was 1 year (IQR 1.0, 1.1). The median change in CortBMD Z-score was Ϫ0.07 (IQR Ϫ0.55, 0.40). Although the magnitude of the median Each of the following variables when added to the base model was associated with the change in CortBMD Zscore: baseline calcium (␤ ϭ Ϫ.50, P ϭ .008); change in calcium (␤ ϭ .71, P ϭ .002); change in iPTH (␤ ϭ Ϫ.28, P Ͻ .001); change in 24,25(OH) 2 D (␤ ϭ Ϫ.15, P ϭ .03); and worsening renal function (␤ ϭ 0.10, P ϭ .01). Given the strong positive association between CortBMD Z-score and calcium both cross-sectionally and longitudinally, we hypothesized that calcium may have a greater impact on the growing skeleton. We confirmed that the change in serum calcium was significantly associated with the change in CortBMD Z-score among participants with greater growth (P for interaction ϭ .02). The Spearman's rho for the association between change in CortBMD Zscore and change in calcium was 0.04 (P ϭ .83) if the change in the tibia length was 0 as compared with 0.39 (P ϭ .02) if the change in the tibia length was 10 mm or greater (Figure 1) . In multivariable analysis, this interaction and the opposing effects of calcium and iPTH persisted; increases in serum calcium were associated with increases in CortBMD Z-score among those participants who were growing (Table 6 ). Increases in iPTH and higher baseline 1,25(OH) 2 D were associated with decreases in CortBMD Z-score in all participants. Change in 24,25(OH) 2 D was not significant after adjustment for renal function. The R 2 of this model was 0.61, indicating that it explained 61% of the variability in change in CortBMD Z-score remaining after the normal variability explained by age, race, and sex was captured by the Z-score. Substituting change in 1-84 PTH for iPTH did not impact model findings. 
Fracture
Eleven of 170 participants (6.5%) sustained a fracture after their baseline visit (incidence of 556 per 10 000 person-years). Median follow-up time was 1.1 years (IQR 1.0, 1.2). Cox regression analysis adjusted for age and sex demonstrated that lower baseline CortBMD Z-score was associated with fracture; the HR per SD decrease in CortBMD was 1.75 [95% confidence interval (CI) 1.15-2.67; P ϭ .009]. The mean CortBMD Z-score was Ϫ0.93 in those who subsequently fractured, compared with 0.08 in those who did not (P ϭ .02). Fracture sites included clavicle (n ϭ 1), tibia (n ϭ 3), foot (n ϭ 3), toes (n ϭ 2), and radius/ulna (n ϭ 2). Associated activities included snowboarding, dancing, running, soccer, scooter racing, fall with foot caught in chair, football, struck by a slow-moving car tire, roughhousing, car accident, and fall downstairs. Given that a prior population-based study demonstrated that dual-energy x-ray absorptiometry (DXA) results contributed to fracture risk in children, regardless of trauma severity, all fractures were included in the primary analysis (24) . Excluding the 2 events involving cars, the HR per SD decrease in CortBMD increased to 1.89 (95% CI 1.19 -2.99; P ϭ .007).
Discussion
This is the first study to assess the independent relations between comprehensive measures of mineral metabolism and volumetric cortical BMD in CKD, and the first to assess whether lower CortBMD was associated with subsequent fractures. In cross-sectional and longitudinal analyses, lower calcium and greater iPTH and 1,25(OH) 2 D were the main determinants of CortBMD Z-score deficits. Furthermore, lower baseline CortBMD Z-score was associated with an increased risk of subsequent fracture. The incidence of fracture in our cohort was 4-fold higher than that reported in a large populationbased study of fracture epidemiology in children and adolescents (133 per 10 000 person-years) (25) .
The strong positive association between serum calcium and CortBMD Z-score is a novel finding with potentially important clinical implications. Our study corroborates and complements the recent histomorphometry findings of Wesseling-Perry et al (3); in 52 children with CKD, defective mineralization was associated with lower serum calcium and higher iPTH concentrations. Furthermore, we demonstrated an interaction between changes in calcium and linear growth, ie, that increases in serum calcium were strongly associated with increases in CortBMD Zscore, but only among children who were growing.
Observational studies (26, 27 ) and 2 randomized trials (28, 29) have linked the use of calcium-based phosphate binders with increased arterial calcification in patients with end-stage renal disease and raised concern about excess calcium load in this population (30) . In the 1 study that included children, none of the patients younger than 20 years of age had evidence of coronary artery calcification (26) . Our findings provide a cautionary note regarding the calcium requirements of the growing skeleton for optimal long-term bone health. In healthy children, positive calcium balance results in average peak calcium accretion rates of 359 and 284 mg/d in boys and girls, respectively (31) . As previously reported in this cohort, greater increases in iPTH were associated with greater de- Cell contents are difference in Z-score (SD), with P value in parentheses. All models are adjusted for age and study site. a Final model. clines in CortBMD Z-score as anticipated, given the high bone turnover state of hyperparathyroidism (32, 33) . Importantly, the positive association between CortBMD Zscore and calcium persisted after adjustment for the inverse relationship (lower calcium results in greater iPTH) between calcium and iPTH. Although 1,25(OH) 2 D has both anabolic and catabolic actions on bone, its primary effect in preclinical models is resorptive (34) . Increased 1,25(OH) 2 D concentrations in mice with intestine-specific vitamin D receptor inactivation were shown to promote bone turnover, leading to osteopenia, and suppress matrix mineralization (35) . Compelling clinical evidence is provided by the recent report that the increased fracture risk observed after yearly high-dose oral vitamin D 3 was associated with the 1,25(OH) 2 D level 3 months after its administration (36) . Our findings of an inverse association between 1,25(OH) 2 D levels and CortBMD Z-score, independent of PTH, are consistent with a resorptive effect. After adjustment for its strong positive association with 1,25(OH) 2 D (as its substrate), greater 25(OH)D concentrations were associated with higher CortBMD Z-score cross-sectionally, and this was partially explained by iPTH and calcium.Anotherimportantfindingwas the comparable relations between CortBMD Z-score and total vs free and bioavailable 25(OH)D. Recently a study in healthy young adults reported that free and bioavailable 25(OH)D were more strongly correlated with DXA spine BMD than total 25(OH)D (20) . Using the same DBP assay and formulae to estimate free and bioavailable 25(OH)D, we found no significant difference in the correlation coefficients between CortBMD Z-score and total, free, and bioavailable 25(OH)D, suggesting that at least in terms of CortBMD, total 25(OH)D provides an adequate assessment of nutritional vitamin D status in CKD. This is the fourth pediatric chronic disease population in which we have demonstrated that glucocorticoid therapy is associated with greater CortBMD Z-score (9, 23, 37) . We attributed this to glucocorticoid actions on osteoblasts and osteocytes to suppress bone formation (38) with resultant accumulation of older cortical bone of greater density. Although not the focus of this paper, we recently examined associations between concurrent glucocorticoid dose and CortBMD Z-score in children with nephrotic syndrome and normal renal function and demonstrated that greater glucocorticoid exposure, lesser linear growth, and lesser expansion of cortical area were independently associated with greater increases in CortBMD Z-score (39) . These findings support our hypothesis that glucocorticoid-induced suppression of bone formation results in accumulation of older cortical bone of greater material density independent of gains in bone length and dimensions. Given that participants on glucocorticoids at baseline had lesser increases in tibia length over the follow-up interval, the association between glucocorticoids and Cort-BMD Z-score may have been partially confounded by growth.
The lack of bone biopsy data is a limitation of this study. Without histomorphometry, it cannot be deter- Also adjusted for age, study site, baseline CortBMD Z-score, baseline calcium, and change in renal function. a Natural log transformed.
mined whether cortical deficits are secondary to increased porosity and/or decreased mineralization. However, a prior quantitative computed tomography study demonstrated reduced CortBMD in children with rickets, suggesting our observations are consistent with impaired mineralization (21) . The lack of measures of ionized calcium is an additional limitation; however, total calcium was corrected for serum albumin. The longitudinal analysis may have been subject to bias; however, comparison of baseline characteristics revealed that those without longitudinal data differed only in the distribution of sex and CKD stage, both of which were accounted for in the analysis. There was substantial heterogeneity in participant characteristics, but the predialysis study population was representative based on comparison to the Chronic Kidney Disease in Children Study (40) . Finally, although the longitudinal component strengthens the cross-sectional findings, the observational nature of the study limits conclusions regarding causality. This study has several important strengths. It is the largest longitudinal study of bone structure and mineral metabolism in childhood CKD. Unlike DXA, the volumetric outcome of CortBMD generated by pQCT is not confounded by bone size; this is critical in pediatric CKD, given the burden of short stature. The large sample of healthy reference participants allowed for the generation of age-, sex-, and race-specific Z-scores. This study is unique in its comprehensive assessment of mineral metabolism with simultaneous and longitudinal measures of vitamin D metabolites, iPTH, FGF-23, calcium, and phosphorus. Furthermore, the measurement of DBP allowed for the novel analyses of the relations between free and bioavailable 25(OH)D and CortBMD Z-score. Finally, the prospective collection of fracture data allowed us to relate cortical BMD to this relevant outcome.
In summary, we demonstrated that calcium, iPTH, and 1,25(OH) 2 D are important and independent correlates of CortBMD Z-score and that calcium is of particular importance in the growing skeleton. Cortical bone comprises 80% of skeletal mass, and children are more likely to fracture the cortical-rich appendicular skeleton. This is the first pediatric study to demonstrate that lower cortical density is associated with increased risk of fracture in CKD, making it an important therapeutic target.
